Skip to main content

Table 1 Patient characteristics

From: Multiday corticosteroids in cancer chemotherapy delay the diagnosis of and antimicrobial administration for febrile neutropenia: a double-center retrospective study

No. of patients (%)a

Variable

Multidayb

Non-multidayc

P

(n = 41)

(n = 172)

Age (year)

 Median (range)

65(42–87)

62(24–85)

 

  < 65

20(49)

99(58)

0.38d

Sex

 Male

28(68)

79(46)

0.014d

ECOG PS

 0

15(37)

66(38)

0.52e

 1

18(44)

83(48)

 

 2

7(17)

16(9.3)

 

 3

1(2.4)

7(4.1)

 

CCr (mL/min)f

 Median (range)

71.2(39.5–98.0)

74.9(31.8–99.8)

 

  < 50

3(7.3)

18(11)

0.77d

T-Bil (mg/dL)

 Median (range)

1.1(0.2–2.1)

0.9(0.1–2.4)

 

  < 2

39(95)

162(94)

1.0d

FN rate of regimeng

 Low (< 10%)

25(61)

104(61)

0.92e

 Moderate (10 to < 20%)

13(32)

52(30)

 

 High (≥20%)

3(7.3)

16(9.3)

 

Stage

 II

8(20)

25(15)

0.072e

 III

9(22)

71(41)

 

 IV

24(59)

76(44)

 

CYP3A4 inhibitor

 Use

6(15)

22(13)

0.80d

MASCC score

 High risk (≤20)

16(39)

77(45)

0.60d

Blood culture

 Positive

6(15)

13(7.6)

0.21d

  1. aThe sum of the percentages may not equal 100% because of rounding off
  2. bThe multiday group included patients who were administered corticosteroid every day from the initiation of chemotherapy to onset of FN irrespective of its dosage
  3. cThe non-multiday group included patients who were administered corticosteroid without every day from the initiation of chemotherapy to onset of FN irrespective of its dosage
  4. dFisher’s exact test
  5. echi-squared test
  6. fThe values were calculated using the Cockcroft-Gault formula
  7. gEach rate was based on previous clinical studies [2,3,4,5,6]
  8. ECOG PS Eastern Cooperative Oncology Group performance status, CCr creatinine clearance, T-Bil total bilirubin, FN febrile neutropenia, CYP cytochrome P450, MASCC Multinational Association for Supportive Care in Cancer